We came across a bullish thesis on Sarepta Therapeutics, Inc. (SRPT) on Disruptive analytics’ Substack by Magnus Ofstad. In ...
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) yesterday and set a ...
Analysts at HC Wainwright raised their FY2024 earnings estimates for Sarepta Therapeutics in a note issued to investors on ...
In a report released today, Biren Amin from Piper Sandler maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a ...
Sarepta Therapeutics' Elevidys for DMD shows revenue potential, with market cap justified at $11.4bn and potential for >50% ...
3d
Assenagon Asset Management S.A. trimmed its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 62.2% in the ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $151.64, a high estimate of ...
A report questions the FDA's accelerated approval process citing Sarepta and Biogen therapies as examples. Read more here.
Sarepta Therapeutics’ Duchenne muscular dystrophy therapy Elevidys handily beat analysts’ expectations in the fourth quarter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback